SFPIA
JUNO

Stevens First Principles Investment Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200
Closed -$8K – 214
2015
Q3 		$8K Buy
+200
New +$8.77K 0.01% 172

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens First Principles Investment Advisors's JUNO Position: Q4 2015 in Review

Stevens First Principles Investment Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2015, closing a stake of 200 shares — an estimated $8K sold.

Stevens First Principles Investment Advisors first reported a position in JUNO in Q3 2015 and held it in 1 quarter. The position peaked at $8K in Q3 2015. 160 funds tracked by Wall St. Rank hold JUNO as of Q4 2015.

  • Stevens First Principles Investment Advisors reported no remaining Juno Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 200 Juno Therapeutics, Inc. shares in Q4 2015, an estimated $8K.
  • Stevens First Principles Investment Advisors first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Stevens First Principles Investment Advisors's Juno Therapeutics, Inc. position peaked at $8K in Q3 2015.
  • 160 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q4 2015, filed 29 Jan 2016.